Table 4.
Cox regression analysis on new-onset type2 DM according to years of exposure
| (N) | Unadjusted Hazard Ratioa | Adjusted Hazard Ratioa | ||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | HR | |||
| Non-statin (5273) | 1.000 | 1.000 | ||||||
| Atorvastatin (1071) | 1.791 | 1.598 | 2.009 | < 0.0001 | 1.942 | 1.661 | 2.269 | 1.942 |
| < 2 years (137) | 1.027 | 0.846 | 1.248 | 0.7853 | 0.989 | 0.8 | 1.222 | 0.989 |
| 2–5 years (127) | 1.007 | 0.822 | 1.234 | 0.9448 | 1.005 | 0.791 | 1.277 | 1.005 |
| ≥ 5 years (807) | 1.907 | 1.563 | 2.327 | < 0.0001 | 1.83 | 1.487 | 2.252 | 1.83 |
| Lovastatin (771) | 1.847 | 1.624 | 2.101 | < 0.0001 | 1.915 | 1.621 | 2.263 | 1.915 |
| < 2 years (103) | 1.07 | 0.862 | 1.328 | 0.5382 | 1.005 | 0.793 | 1.275 | 1.005 |
| 2–5 years (92) | 1.113 | 0.885 | 1.401 | 0.3599 | 1.068 | 0.826 | 1.382 | 1.068 |
| ≥ 5 years (576) | 1.942 | 1.551 | 2.431 | < 0.0001 | 1.846 | 1.458 | 2.337 | < 0.0.0001 |
| Pravastatin (391) | 1.662 | 1.39 | 1.986 | < 0.0001 | 1.758 | 1.429 | 2.164 | < 0.0001 |
| < 2 years (42) | 0.914 | 0.677 | 1.234 | 0.5582 | 0.981 | 0.706 | 1.363 | 0.9093 |
| 2–5 years (50) | 1.256 | 0.946 | 1.666 | 0.1148 | 1.236 | 0.899 | 1.699 | 0.1911 |
| ≥ 5 years (299) | 1.779 | 1.335 | 2.371 | < 0.0001 | 1.633 | 1.211 | 2.203 | 0.0013 |
| Rosuvastatin (243) | 1.723 | 1.381 | 2.15 | < 0.0001 | 1.932 | 1.511 | 2.471 | < 0.0001 |
| < 2 years (32) | 0.931 | 0.653 | 1.328 | 0.6927 | 0.826 | 0.547 | 1.247 | 0.3635 |
| 2–5 years (30) | 1.727 | 1.198 | 2.491 | 0.0034 | 1.712 | 1.133 | 2.586 | 0.0107 |
| ≥ 5 years (181) | 1.578 | 1.053 | 2.365 | 0.0271 | 1.587 | 1.051 | 2.398 | 0.0282 |
| Simvastatin (2711) | 1.669 | 1.531 | 1.819 | < 0.0001 | 1.794 | 1.567 | 2.055 | < 0.0001 |
| < 2 years (310) | 0.93 | 0.802 | 1.078 | 0.3341 | 0.912 | 0.776 | 1.071 | 0.2617 |
| 2–5 years (290) | 0.988 | 0.846 | 1.155 | 0.8804 | 0.979 | 0.824 | 1.163 | 0.8103 |
| ≥ 5 years (2111) | 1.967 | 1.701 | 2.274 | < 0.0001 | 1.916 | 1.647 | 2.228 | < 0.0001 |
aModel was adjusted for age, sex, income level, urbanization of residence, Charlson comorbidity index, comorbidities (hypertension, prediabetes, liver disease, renal disease, metabolic disorder, family history of diabetes, obesity, hypothyroidism), number of outpatient visits in the previous 3 years, number of hospitalizations in the previous 3 years, comedications (fibrates, niacin, corticosteroids, hypertension medications). *p < 0.001. HR, hazard ratio; CI, confidence interval